On September 27, Pfizer announced that its self-developed anti-covid19 oral drug PF-07321332 will be used in Japan as soon as the end of this year.
In less than a week, Merck, a well-known American pharmaceutical company, also announced the success of its oral drug development, which will effectively reduce the severity of new coronary diseases by 50%. It will apply for the US EUA (Emergency Use Authorization) and is expected to be marketed in the United States by the end of this year. .